Dark papillary muscles sign is a new prognostic indicator in patients with dilated cardiomyopathy: A multi-center

Rongxue Shan1, Yan Gao2, Wenxian Wang3

  • 1School of Medicine, Shandong First Medical University, Jinan, Shandong 271099, China; Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.

PubMed

Insights

Left ventricular papillary muscle anomalies, identified as Dark-Paps via cardiac magnetic resonance, are a significant predictor of major adverse cardiac events in dilated cardiomyopathy patients. This finding offers improved prognostic insights beyond traditional clinical models.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Biomarkers

Background:

  • Dilated cardiomyopathy (DCM) is a significant cause of heart failure.
  • The prognostic value of left ventricular (LV) papillary muscle anomalies in DCM remains unclear.
  • Cardiac magnetic resonance (CMR) allows detailed assessment of cardiac structures.

Purpose of the Study:

  • To evaluate the prognostic significance of LV papillary muscle anomalies in DCM patients.
  • To investigate the association between papillary muscle features and major adverse cardiac events (MACE).
  • To determine if CMR-derived papillary muscle features improve risk stratification in DCM.

Main Methods:

  • Retrospective analysis of 369 DCM patients who underwent CMR.
  • Assessment of LV papillary muscle features including thickness, attachment, signal intensity.
  • Identification of end-systolic signal hypointensity as 'Dark-Paps'.
  • Follow-up for MACE and survival analysis using Kaplan-Meier and multivariate models.

Main Results:

  • 119 patients (32.2%) presented with Dark-Paps.
  • 141 patients (38.2%) experienced MACE during a median follow-up of 22 months.
  • Dark-Paps was associated with significantly lower MACE-free survival (p < 0.001).
  • Dark-Paps independently predicted MACE (HR: 3.49; p < 0.001) and improved prognostic model discrimination (C-statistic improvement from 0.652 to 0.777).

Conclusions:

  • Dark-Paps identified via CMR is a potent independent predictor of MACE in DCM.
  • Dark-Paps provides significant additional prognostic value beyond established clinical factors.
  • This finding enhances risk stratification for DCM patients.
Abstract